Avalo posts updated investor presentation highlighting IL-1β pipeline focus

Avalo Therapeutics, Inc.

Presentation dated June 2025 reiterates mission to advance novel IL-1β therapies for unmet medical needs.
No new clinical data, financial results, or guidance included in the investor deck.
Company to use presentation in meetings with investors; no material change in strategy disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.